The FDA released its review of Isentress ahead of a panel meeting next Wednesday that is being called to make recommendations to the agency about whether the drug should be approved.
The agency said the potential risks of Isentress include rash, liver injuries, muscle problems and cancer. The FDA said there was a higher number of cancers seen among patients in clinical studies receiving Isentress but said the "imbalance" appeared to reflect the low rate of cancers seen in the placebo group. read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment